More stories

  • in

    Panera Bread files to go public again through IPO

    Panera Bread has confidentially filed to go public again, CNBC has learned
    The restaurant chain has been signaling for months that it’s interested in an initial public offering.
    JAB Holding took the company private in 2017 for $7.5 billion.

    A Panera Bread mango yuzu citrus charged lemonade is displayed at a Panera Bread restaurant in Novato, California, on Nov. 1, 2023.
    Justin Sullivan | Getty Images

    Panera Bread has confidentially filed to go public again, people familiar with the matter told CNBC.
    The restaurant chain, known for its soups, sandwiches and bagels, has been signaling for months that it’s looking to go public through an initial public offering. In May, Panera announced a CEO transition and said the leadership changes were “in preparation for its eventual IPO” — amid a two-year IPO drought that ended in the fall.

    Mediterranean restaurant chain Cava, whose chair is Panera founder Ron Shaich, was among the trickle of companies that went public this year. Investors had mixed reactions to the slate of offerings.
    Panera isn’t alone in hoping market conditions improve in 2024. Chinese-founded fast-fashion giant Shein confidentially filed to go public Monday, and Bloomberg reported Tuesday that Reddit and Skims could also be in next year’s IPO class.
    Panera declined to comment to CNBC. The news was first reported by the Financial Times.
    The company was last publicly traded in 2017. JAB Holding, the investment arm of the Reimann family, bought the company for $7.5 billion. It added Panera to a portfolio that, at that time, included Keurig and Krispy Kreme.
    In recent years, however, JAB has been reworking its portfolio. In 2021, it sold Au Bon Pain to a Yum Brands franchisee and took Krispy Kreme public.

    JAB also tried to take Panera public again that year. But in 2022, Panera called off its deal with Danny Meyer’s special purpose acquisition company. The unusual arrangement would have exchanged shares of USHG Acquisition for the sandwich chain’s stock and allowed the company to survive a merger with Panera’s subsidiary Rye Merger.
    However, Panera scrapped those plans, citing market conditions.
    But the chain’s current attempt to go public comes as the restaurant has drawn scrutiny for other reasons. The company was recently sued for its “charged lemonade.” The plaintiffs allege the drink caused the death of their college-age daughter, who had a heart condition.Don’t miss these stories from CNBC PRO: More

  • in

    Media stocks jump after report says Apple, Paramount are discussing streaming bundle

    Warner Bros. Discovery and Paramount Global shares jumped Friday.
    Apple and Paramount are discussing bundling their streaming services, The Wall Street Journal reported.
    Warner Bros. Discovery has been open to bundling its Max service with rivals.

    Jakub Porzycki | Nurphoto | Getty Images

    Media stocks jumped Friday following a Wall Street Journal report that Apple and Paramount Global are in early-stage talks to offer a bundle of the two company’s streaming platforms.
    The companies have talked about bundling Apple TV+ and Paramount+ in an offering that would cost less than subscribing to the two separately, The Wall Street Journal reported Friday.

    Shares of Paramount closed up nearly 10% Friday, while Warner Bros. Discovery, which owns streaming service Max, closed up more than 8%. Paramount is down about 6% on the year, while Warner Bros. Discovery, which reported a streaming profit in the third quarter, is up about 19%.
    Apple and Paramount did not immediately respond to CNBC’s request for comment.
    Paramount+ and Apple TV+ could be an ideal match for a bundle given their differing content strategies. Apple TV+ is known to offer a robust library of exclusive and prestige content, while Paramount+ boasts a larger back-catalog of recognizable TV shows and movies.
    The report comes as talk heats up in the media industry about bundling rival streaming services together.
    Streaming leader Netflix and Max entered into an agreement with Verizon to bundle the two services at a reported $10 a month, less than the $17 the combination would normally cost, the Journal previously reported. Liberty Media Chairman and Warner Bros. Discovery board member John Malone has often discussed what streaming bundles could look like. Disney currently offers a bundle of Hulu, Disney+ and ESPN+.

    The trend has extended beyond streaming. Following a dispute earlier this year, Disney and Charter entered into an agreement where some Spectrum customers would gain access to the ad-supported Disney+ plan, a move some experts predict could become more common.
    An Apple partnership could be a strong opportunity to help Paramount pivot in the rapidly changing media environment. Paramount’s controlling shareholder Shari Redstone has been open to making big deals, CNBC has reported, as the company suffers from declining revenue and streaming losses.Don’t miss these stories from CNBC PRO: More

  • in

    Fed Chair Powell calls talk of cutting rates ‘premature’ and says more hikes could happen

    Federal Reserve Chairman Jerome Powell on Friday pushed back on market expectations for aggressive interest rate cuts ahead.
    “It would be premature to conclude with confidence that we have achieved a sufficiently restrictive stance, or to speculate on when policy might ease,” Powell said in a speech.
    However, the remarks gave some credence to the idea that the Fed at least is done hiking as the string of rate hikes since March 2022 have cut into economic activity. Powell noted that inflation “is moving in the right direction.”
    Markets largely took Powell’s comments as dovish, with stock up and Treasury yields down sharply.

    Federal Reserve Board Chairman Jerome Powell speaks during a news conference after a Federal Open Market Committee meeting on September 20, 2023 at the Federal Reserve in Washington, DC.
    Chip Somodevilla | Getty Images

    Federal Reserve Chairman Jerome Powell on Friday pushed back on market expectations for aggressive interest rate cuts ahead, calling it too early to declare victory over inflation.
    Despite a string of positive indicators recently regarding prices, the central bank leader said the Federal Open Market Committee plans on “keeping policy restrictive” until policymakers are convinced that inflation is heading solidly back to 2%.

    “It would be premature to conclude with confidence that we have achieved a sufficiently restrictive stance, or to speculate on when policy might ease,” Powell said in prepared remarks for an audience at Spelman College in Atlanta. “We are prepared to tighten policy further if it becomes appropriate to do so.”
    However, he also noted that policy is “well into restrictive territory” and noted that balance of risks between doing too much or too little on inflation are close to balanced now.

    Markets moved higher following Powell’s remarks, with major averages positive on Wall Street and Treasury yields sharply lower.
    “Markets view today’s comments as inching toward the dovish camp,” said Jeffrey Roach, chief economist at LPL Financial.
    Expectations that the Fed is done raising rates and will move to an easing posture in 2024 have helped underpin a strong Wall Street rally that has sent the Dow Jones Industrial Average up more than 8% over the past month to a new 2023 high.

    Powell’s remarks gave some credence to the idea that the Fed at least is done hiking as the string of rate hikes since March 2022 have cut into economic activity.
    “Having come so far so quickly, the FOMC is moving forward carefully, as the risks of under- and over-tightening are becoming more balanced,” he said.
    “As the demand- and supply-related effects of the pandemic continue to unwind, uncertainty about the outlook for the economy is unusually elevated,” he added. “Like most forecasters, my colleagues and I anticipate that growth in spending and output will slow over the next year, as the effects of the pandemic and the reopening fade and as restrictive monetary policy weighs on aggregate demand.”
    A Commerce Department report Thursday showed that personal consumption expenditures prices, the Fed’s preferred inflation gauge, were up 3% from a year ago, but 3.5% at a core basis that excludes volatile food and energy prices. Recent sharp declines in energy have been responsible for much of the easing in inflation.
    Powell said the current levels are still “well above” the central bank’s goal. Noting that core inflation has run at a 2.5% annual rate over the past six months, Powell said, “while the lower inflation readings of the past few months are welcome, that progress must continue if we are to reach our 2 percent objective.”
    “Inflation is still running well above target, but it’s moving in the right direction,” he said. “So we think the right thing to be doing now is to be moving carefully, thinking carefully about about how things are going on letting letting the data tell us what the story is. The data will tell us whether we’ve done enough or whether we need to do more.”
    After inflation hit its highest level since the early 1980s, the Fed enacted a series of 11 interest rate hikes, taking its policy rate to the highest in 22 years at a target range between 5.25%-5.5%. The FOMC at its past two meetings kept rates level, and multiple officials have indicated they think the federal funds rate is probably at or near where it needs to be.
    The Fed’s next meeting is Dec. 12-13.
    “The strong actions we have taken have moved our policy rate well into restrictive territory, meaning that tight monetary policy is putting downward pressure on economic activity and inflation,” Powell said. “Monetary policy is thought to affect economic conditions with a lag, and the full effects of our tightening have likely not yet been felt.”

    Traders expect cuts

    Market pricing Friday morning indicated that the Fed indeed is done hiking and could start cutting as soon as March 2024, according to the CME Group. Moreover, futures are pointing to cuts totaling 1.25 percentage points by the end of the year, the equivalent of five quarter percentage point reductions.
    However, neither Powell nor any of his fellow officials have provided any indication that they’re thinking about cuts, with the chair adhering to data dependence for future decisions rather than any preset course.
    “We are making decisions meeting by meeting, based on the totality of the incoming data and their implications for the outlook for economic activity and inflation, as well as the balance of risks,” Powell said.
    Addressing the economic data, Powell characterized the labor market as “very strong,” through he said a reduced pace of job creation is helping bring supply and demand back in line.
    Don’t miss these stories from CNBC PRO: More

  • in

    Not saving in your 401(k)? Your employer may re-enroll you

    More companies are doing 401(k) plan reenrollments every year.
    While automatic enrollment generally pertains to new hires, a reenrollment is like automatic enrollment for everyone else who doesn’t currently save in the company’s 401(k).
    Some employers may even reenroll workers who don’t contribute a baseline share of their paychecks.

    A modern office space with a variety of plants on display and some employees working together at computer desks.
    Tom Werner | Digitalvision | Getty Images

    If you elected not to participate in your company’s 401(k) plan, your employer may have other ideas.
    The concept of 401(k) plan “reenrollment” has been gaining traction. That means companies are more regularly choosing to automatically sweep workers into their workplace plan if they don’t currently participate.

    While automatic enrollment, which has also gained popularity, generally applies to new hires, reenrollments typically apply to all workers who don’t currently save in the 401(k).
    As of 2022, about 10% of companies that offer a retirement plan reenroll workers into the 401(k) every year, according to a recent survey by the Plan Sponsor Council of America, a trade group. That share is up from 4% a decade earlier.

    More from Your Money:

    Here’s a look at more stories on how to manage, grow and protect your money for the years ahead.

    The calculus is often one of retirement security and trying to help boost workers’ savings, said Sean Deviney, a certified financial planner based in Fort Lauderdale, Florida.
    “A lot of times employees make their [401(k)] election when they’re hired and never look at it again,” said Deviney, director at Provenance Wealth Advisors.
    Most companies, about 85%, direct workers’ savings into target-date funds if they’re automatically enrolled, according to PSCA data.

    Workers receive a notification from their employer ahead of reenrollments and have the chance to opt out or reduce their contribution. Employers’ hope is that inertia will cause workers to stay in the plan rather than opt out.

    Some companies may elect to do this as a one-time exercise instead of annually, Deviney said. Others may also choose to reenroll workers who are currently participating in the company 401(k) but bump them up to a higher savings rate, he said.
    Companies may also derive a long-term financial benefit from such policies. For example, better worker finances can boost employee productivity and happiness on the job and allow them to retire at a younger age, perhaps saving companies money on future payroll and health costs.
    Companies may also decide against adopting reenrollment policies out of fear of being too paternalistic, Deviney said. It may also raise employer costs too much, especially if the company offers a 401(k) match, he said. More

  • in

    Amazon buys SpaceX rocket launches for Kuiper satellite internet project

    Amazon bought three rocket launches from SpaceX for its Project Kuiper internet satellites, the tech giant announced on Friday.
    The move is a surprise from Amazon, given the company’s Kuiper system aims to compete with Elon Musk’s Starlink in the satellite broadband market.
    SpaceX, the most active rocket operator in the world, has been adamant that it will launch Starlink competitors on its rockets.

    A Falcon 9 rocket launches a Starlink mission on January 31, 2023 from Vandenberg Space Force Base in California.

    Amazon bought three rocket launches from SpaceX for its Project Kuiper internet satellites, the tech giant announced on Friday.
    The move is a surprise from Amazon, given the company’s Kuiper system aims to compete with Elon Musk’s Starlink in the satellite broadband market. Both Starlink and Kuiper represent multibillion-dollar efforts to create networks with thousands of satellites in orbit to serve customers ranging from consumers to governments.

    Amazon previously made a blockbuster order for launches from three of SpaceX’s top rocket rivals, including Jeff Bezos’ Blue Origin — a decision which came under scrutiny in a shareholder lawsuit against Amazon earlier this year that alleged Bezos’ rivalry with fellow billionaire Musk led to snubbing SpaceX.
    While Bezos founded both Amazon and Blue Origin, the companies are separate entities.

    Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

    SpaceX, the most active rocket operator in the world, has been adamant that it will continue launching Starlink competitors on its rockets. The company previously launched a number of other companies’ broadband satellites to orbit and signed deals for future launches as well.
    In Friday’s announcement, Amazon said it signed with SpaceX for three Falcon 9 launches in mid-2025. Financial terms of the agreement were not disclosed.

    The SpaceX deal marks the latest shift in Amazon’s strategy as the company pushes to get Kuiper to space in time to meet federal regulations. Federal Communications Commission rules require that Amazon deploy half of its planned 3,236 satellites in orbit by July 2026.

    Amazon has orders for more than 77 launches from Blue Origin, United Launch Alliance, Arianespace and ABL. But delays in the development of those rockets have led Amazon to change launch plans before: The company twice switched the rocket that its first pair of Kuiper prototypes would fly on, in an effort to expedite development, before the mission launched in October.
    The Kuiper prototypes completed testing successfully, Amazon announced last month, with the company pushing to begin manufacturing commercial satellites for launches next year.
    Amazon expects to invest upwards of $10 billion to build Kuiper. Earlier this year the company broke ground on a $120 million pre-launch processing facility in Florida. More

  • in

    Southwest, pilots union near a preliminary labor deal, the last of the major U.S. airlines

    Southwest and its pilots union are closing in on a labor deal that would end months of contentious negotiations.
    The new contract will likely include significant pay raises as well as improvements to retirement benefits and scheduling.
    If a preliminary agreement is approved by Southwest pilots union board in the coming weeks, it would then go to the pilots for a ratification vote.

    A Southwest Airlines Boeing 737-700 aircraft lands at Ronald Reagan Washington National Airport in Arlington, Virginia, May 7, 2023.
    Nicolas Economou | Nurphoto | Getty Images

    Southwest Airlines and its pilots union are closing in on a new contract that would raise pay for the carrier’s more than 11,000 aviators and end months of contentious negotiations, weeks ahead of the crucial holiday travel season.
    The company and the union have agreed on pay, retirement and other items but are working on an implementation schedule, the Southwest Airlines Pilots Association said in a message to its members on Thursday.

    Delta Air Lines, United Airlines and American Airlines have already finalized multibillion-dollar labor agreements with pilots this year as unions pushed for pay hikes, better scheduling and other improvements after the Covid pandemic derailed contract talks.
    If a preliminary agreement is approved by the Southwest pilots union board in the coming weeks, it would then go to the pilots for a ratification vote.
    The union and the airline declined to provide specifics of the deal.
    Southwest and the union “are working hard to close out the few remaining items,” an airline spokesman told CNBC. “Southwest remains committed to reaching an agreement that rewards our Pilots and places them competitively in the industry.”
    Southwest reached a preliminary agreement with its flight attendants union earlier this fall that includes 36% pay increases for cabin crew members.

    A labor deal between the company and its pilots would end a period of tense negotiations, which recently included laying groundwork for a potential strike, though strikes are extremely rare in the airline industry.
    It would also become the latest in a string of big labor deals this year, including agreements between Hollywood studios and actors, and the studios and writers, as well as between automakers and the United Auto Workers union, following strikes. More

  • in

    Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

    Pfizer said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. 
    But the pharmaceutical giant said it still plans to release phase two trial data on a once-a-day version of the drug, known as danuglipron, in the first half of 2024.
    The new data is a blow to Pfizer and its hopes to win a $10 billion slice of the booming weight loss drug market, which CEO Albert Bourla previously said could eventually grow to $90 billion.

    Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost significant weight but had trouble tolerating the drug in a mid-stage clinical study. 
    The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant share of patients also stopped taking the drug.

    “At this time, twice-daily danuglipron formulation will not advance into Phase 3 studies,” the company said.
    But Pfizer said it still plans to release phase two trial data on a once-a-day version of the drug in the first half of 2024, which will “inform a path forward.” The pharmaceutical giant will wait to see that data before deciding whether to start a phase three study on the once-daily pill, which Wall Street views as the more competitive form of the treatment.
    Shares of Pfizer fell 4% in premarket trading Friday after it announced the trial results.
    Still, the data on the twice-daily drug is a blow to Pfizer’s hopes to win a $10 billion slice of the booming weight loss drug market, which CEO Albert Bourla has said could grow to $90 billion. The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year. 
    But investors have been pessimistic about Pfizer’s potential in the weight loss drug space since the company scrapped a different once-daily pill in June and proceeded with the less attractive danuglipron. Now, Friday’s data puts Pfizer even further behind the dominant players in the weight loss drug market, Eli Lilly and Novo Nordisk, which are racing to develop more convenient pill versions of their blockbuster weight loss and diabetes injections. 

    Pfizer’s phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. The trial examined the drug’s effect on weight loss after 26 or 32 weeks, at different dosage amounts ranging from 40 milligrams to 200 milligrams.
    Like Novo Nordisk’s Wegovy and Ozempic, Pfizer’s pill works by mimicking a hormone produced in the gut called GLP-1, which signals to the brain when a person is full.
    Pfizer said the trial on danuglipron met the primary goal of demonstrating “statistically significant” reductions in body weight.
    Patients who took the pill twice a day lost 6.9% to 11.7% of their body weight on average at 32 weeks, and from 4.8% to 9.4% at 26 weeks.
    Meanwhile, patients on a placebo gained 1.4% of their body weight at 32 weeks and 0.17% at 26 weeks.
    When adjusting for the difference between the weight gain observed in patients who took the placebo, Pfizer’s twice-daily pill caused 8% to 13% weight loss on average at 32 weeks and 5% to 9.5% at 26 weeks.
    The company said high rates of adverse events were observed among patients in the study, with up to 73% experiencing nausea, up to 47% vomiting and up to 25% experiencing diarrhea. More than 50% of patients across all dose sizes stopped taking the pill, compared to roughly 40% among those on the placebo, according to Pfizer.
    No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer’s other discontinued weight loss pill.
    Data from the phase two trial will be presented at a future scientific conference or published in a peer-reviewed journal.

    Wall Street’s expectations

    The tolerability issues align with some analysts’ predictions ahead of the data release. 
    Leerink Partners analyst David Risinger wrote in a Monday note that the proportion of patients who discontinue treatment with Pfizer’s twice-daily danuglipron in the phase two trial would likely be higher than those who stopped taking a once-daily pill from Eli Lilly.
    By comparison, 10% to 21% of patients who took Eli Lilly’s pill, orforglipron, in a mid-stage trial discontinued the treatment at 32 weeks due to adverse side effects, he noted.
    Risinger said that’s likely because danuglipron’s total daily dose is far higher, which may cause more adverse effects. Patients on the highest dose size of Pfizer’s pill took 400 milligrams each day, while those on the highest dosage of Eli Lilly’s drug took 45 milligrams a day.
    Pfizer’s phase-two trial also didn’t allow downtitration, or decreasing the dose of a drug over time once a specific response has been achieved. Eli Lilly’s mid-stage trial on its pill did. 
    There is hope that patients will better tolerate the once-daily version of danuglipron compared to the twice-daily form. Pfizer appears to believe a once-daily version of the drug could lessen gastrointestinal side effects, according to some analysts.
    They pointed to Pfizer’s second-quarter earnings call, when the company’s chief scientific officer, Mikael Dolsten, suggested that a once-daily version may improve a patient’s tolerability of the drug, which could lessen the gastrointestinal side effects “that have been seen as limiting” danuglipron.
    But the effects will be unclear until the mid-stage trial data is released next year.
    Notably, the weight loss caused by twice-daily danuglipron appeared to fall short of analysts’ expectations. 
    Ahead of the data release, several analysts said Pfizer’s twice-daily pill has to be about as effective as Eli Lilly’s once-a-day pill to be competitive. That means at least a 14% to 15% weight loss, Cantor Fitzgerald analyst Louise Chen told CNBC earlier this month.
    Risinger also wrote in October that Pfizer’s danuglipron needs to show weight reduction in the “mid-teens” percentages to be considered competitive with Eli Lilly’s pill. 
    Obese or overweight patients who took 45 milligrams of Eli Lilly’s pill once a day lost up to 14.7% of their body weight, or 34 pounds, after 36 weeks, according to the company’s phase-two trial results.
    Eli Lilly’s results appear consistent with the weight reduction caused by a high-dose oral version of Novo Nordisk’s semaglutide – the active ingredient used in the diabetes drug Ozempic and weight loss treatment Wegovy – but came over a shorter trial period.
    More than 2 in 5 adults have obesity, according to the National Institutes of Health. About 1 in 11 adults have severe obesity.
    Clarification: This story was updated to reflect that some weight-loss data was adjusted to include results from the placebo group. More